Eli Lilly shares surge on new obesity pill data. What it means for the stock from here
Jim Cramer said Eli Lilly's new trial data has turned the obesity market into a 'one-horse race.'
Orforglipron also reduced blood sugar levels in obese participants with type 2 diabetes
A significant trial of a daily weight-loss pill has found that it helped people to shed the pounds and reduce th…